Generic version of a drug already on the market, which can suppress and prevent HIV, would still yield 30% profit if the current price was slashed, researchers say
A new drug described as “the closest we have ever been to an HIV vaccine” could cost $40 (£31) a year for every patient, a thousand times less than its current price, new research suggests.
Lenacapavir , sold as Sunlenca by US pharmaceutical giant Gilead, currently costs $42,250 for the first year. The company is being urged to make it available at a thousand times less than that price worldwide.
About Author
More Stories
As a geneticist, I will not mourn 23andMe and its jumble of useless health information | Adam Rutherford
Amazon’s satellite launch designed to compete with Musk’s Starlink cancelled
Tesla stops taking orders in China for two models imported from US